Immunic CEO Joins Board as Director Retires
Immunic, Inc. reported a board change linked to retirement plans.
Rhea-AI Filing Summary
Immunic, Inc. reported a board change linked to retirement plans. On June 29, 2026, director Tamar Howson resigned from the Board and its Compensation Committee as she transitions into retirement. The company states her resignation did not result from any disagreement over operations, policies, or practices.
Following a recommendation from the Nominating and Corporate Governance Committee, the Board appointed Chief Executive Officer Erik Lundgren as a Class II director, effective July 5, 2026. He will serve until the 2028 annual meeting of stockholders. Lundgren will receive no additional compensation for board service, has not joined any board committee, and aside from his existing employment agreement and CEO compensation, the filing notes no related-party transactions requiring disclosure.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Class II director, Nominating and Corporate Governance Committee, Compensation Committee, Item 404(a) of Regulation S-K, +1 more
5 terms
Class II director financial
"the Board appointed Erik Lundgren, the Company’s Chief Executive Officer, to serve as a Class II director of the Board until the 2028 annual meeting"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
Nominating and Corporate Governance Committee financial
"on July 5, 2026, following the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Erik Lundgren"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Compensation Committee financial
"Tamar Howson resigned as a member of the Compensation Committee of the Board of Directors"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Item 404(a) of Regulation S-K regulatory
"there are no transactions involving Mr. Lundgren that would require disclosure under Item 404(a) of Regulation S-K"
Item 5.02 regulatory
"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did Immunic (IMUX) disclose in this Form 8-K?
Immunic disclosed that director Tamar Howson resigned from the Board and its Compensation Committee as she transitions into retirement. The Board then appointed CEO Erik Lundgren as a Class II director to fill the vacancy and serve until the 2028 annual meeting.
Did Tamar Howson resign from Immunic (IMUX) due to any disagreement?
No. The filing states that Tamar Howson’s resignation from the Board and Compensation Committee was not the result of any disagreement with Immunic on operations, policies, or practices. The Board expressed gratitude for her service, dedication, and contributions to the company over her tenure.
What role will Immunic CEO Erik Lundgren hold on the Board?
Erik Lundgren, Immunic’s Chief Executive Officer, has been appointed as a Class II director on the Board. He will serve in this role until the 2028 annual meeting of stockholders and will continue as CEO under his existing employment agreement with the company.
Will Immunic CEO Erik Lundgren receive extra pay as a director?
The filing specifies that Erik Lundgren will not receive any additional compensation for serving as a director. His compensation continues to be governed by his existing employment agreement and arrangements related to his role as Chief Executive Officer of Immunic.
Is Erik Lundgren joining any Immunic (IMUX) board committees?
No. The Form 8-K states that Erik Lundgren has not been appointed to serve on any committee of the Board. His new role is as a Class II director only, alongside his ongoing responsibilities as Chief Executive Officer of Immunic.
AI-generated analysis. How Rhea-AI works. Not financial advice.
